Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Am J Respir Cell Mol Biol. 2020 Jun;62(6):767-782. doi: 10.1165/rcmb.2019-0234OC.
is an unusual, opportunistic fungal pathogen capable of causing pneumonia (PCP) in immunocompromised hosts. Although PCP was discovered >100 years ago, its pathogenesis remains unclear. The inhibitory receptor PD-1 (programmed death 1), a negative regulator of activated T cells, has been reported to take part in tumor escape, immune tolerance, and infection immunity. In this study, we examined the role of the PD-1/PD-L1 (programmed death-ligand 1) pathway in patients with PCP and in mice. The expression levels of PD-1/PD-L1 in patients with PCP and in mice were measured by real-time PCR and flow cytometry. The effects of PD-1 deficiency are demonstrated using wild-type and PD-1 mice. Our data show that infection promotes PD-1/PD-L1 expression; PD-1 deficiency enhances the phagocytic function of macrophages and the pulmonary T-helper cell type 1 (Th1)/Th17 response, which might contribute to clearance; and PD-1 deficiency affects the polarization of macrophages. PCP mice treated with anti-PD-1 antibody showed improved pulmonary clearance of . Collectively, our results demonstrate that the PD-1/PD-L1 pathway plays a role in regulating the innate and adaptive immune responses, suggesting that manipulation of this pathway may constitute an immunotherapeutic strategy for PCP.
是一种不寻常的机会性真菌病原体,能够在免疫功能低下的宿主中引起肺炎(PCP)。尽管 PCP 早在 100 多年前就被发现,但它的发病机制仍不清楚。抑制受体 PD-1(程序性死亡 1)是激活 T 细胞的负调节剂,据报道它参与了肿瘤逃逸、免疫耐受和感染免疫。在这项研究中,我们研究了 PD-1/PD-L1(程序性死亡配体 1)途径在 PCP 患者和小鼠中的作用。通过实时 PCR 和流式细胞术测量 PCP 患者和小鼠中 PD-1/PD-L1 的表达水平。使用野生型和 PD-1 小鼠来证明 PD-1 缺乏的作用。我们的数据表明,感染促进 PD-1/PD-L1 的表达;PD-1 缺乏增强了巨噬细胞的吞噬功能和肺 T 辅助细胞 1(Th1)/Th17 反应,这可能有助于清除;PD-1 缺乏影响巨噬细胞的极化。用抗 PD-1 抗体治疗的 PCP 小鼠显示出肺清除的改善。总之,我们的结果表明 PD-1/PD-L1 途径在调节固有和适应性免疫反应中起作用,提示该途径的操纵可能构成 PCP 的免疫治疗策略。
Am J Respir Cell Mol Biol. 2020-6
Am J Physiol Lung Cell Mol Physiol. 2018-10-4
Front Immunol. 2018-5-25
Int Arch Allergy Immunol. 2018
Microbiol Spectr. 2024-5-2
PLoS Pathog. 2023-5
Heliyon. 2022-11-21
Evid Based Complement Alternat Med. 2022-8-10